🇺🇸 FDA

Intelligence Platform

Patents

Browse 65 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12427170

Universal donor cells

CRISPR THERAPEUTICS AG · Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12344656

Genetically engineered T cells having improved persistence in culture

CRISPR THERAPEUTICS AG · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12344655

Gene-edited natural killer cells

CRISPR THERAPEUTICS AG · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12304968

T-cells expressing anti-LIV1 chimeric antigen receptor

CRISPR THERAPEUTICS AG · Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12263227

Optimized mRNA encoding CAS9 for use in LNPs

CRISPR THERAPEUTICS AG · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12247201

Materials and methods for treatment of autosomal dominant retinitis pigmentosa

CRISPR THERAPEUTICS AG · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12241087

Compositions and methods for differentiating stem cells into NK cells

CRISPR THERAPEUTICS AG · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12227763

Methods and compositions for treating cancer

CRISPR THERAPEUTICS AG · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215316

Materials and methods for treatment of usher syndrome type 2A

CRISPR THERAPEUTICS AG · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215320

Compositions and methods for gene editing by targeting transferrin

CRISPR THERAPEUTICS AG · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12188060

Messenger RNA encoding Cas9 for use in genome-editing systems

CRISPR THERAPEUTICS AG · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12186406

Materials and methods for treatment of hereditary haemochromatosis

CRISPR THERAPEUTICS AG · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12122998

Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosom

CRISPR THERAPEUTICS AG · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12037616

Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions

CRISPR THERAPEUTICS AG · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12016932

Gene editing for hemophilia A with improved factor VIII expression

CRISPR THERAPEUTICS AG · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11958908

Compositions and methods for the depletion of CD117+ cells

CRISPR THERAPEUTICS AG · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11926676

Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and imm

CRISPR THERAPEUTICS AG · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866727

Materials and methods for treatment of glycogen storage disease type 1A

CRISPR THERAPEUTICS AG · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11857574

Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved func

CRISPR THERAPEUTICS AG · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851653

Materials and methods for treatment of alpha-1 antitrypsin deficiency

CRISPR THERAPEUTICS AG · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11833225

Methods and compositions for efficient gene deletion

CRISPR THERAPEUTICS AG · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11827877

Compositions and methods for genomic editing by insertion of donor polynucleotides

CRISPR THERAPEUTICS AG · Granted Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679131

Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved func

CRISPR THERAPEUTICS AG · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679130

Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved func

CRISPR THERAPEUTICS AG · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted